Literature DB >> 106067

Normal adults and subjects with hypogonadotropic hypogonadism respond differently to D-Ser(TBU)6-LH-RH-EA10.

R Smith, R A Donald, E A Espiner, S G Stronach, I A Edwards.   

Abstract

Daily administration of 5microgram of D-Ser(TBU)6-LH-RH-EA10 for one week produced a significant increase in the LH response to GnRH in hypogonadotropic hypogonadal subjects and a significant decrease in the response of normal male adults. Basal plasma testosterone concentrations fell in normal controls but were unchanged in the hypogonadal group.

Entities:  

Keywords:  Androgens; Biology; Clinical Research; Endocrine System; Family Planning; Gonadotropins; Gonadotropins, Pituitary; Hormones; Luteinizing Hormone; Physiology; Pituitary Hormone Releasing Hormones; Reproductive Control Agents; Research Methodology; Testosterone

Mesh:

Substances:

Year:  1979        PMID: 106067     DOI: 10.1210/jcem-48-1-167

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Treatment of cryptorchidism by intranasal synthetic LH-RH and its analogue D-Ser(TBU)6-LHRH-EA10.

Authors:  E Cacciari; E Fréjaville; A Becca
Journal:  Eur J Pediatr       Date:  1982-12       Impact factor: 3.183

2.  Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men.

Authors:  N Faure; F Labrie; A Belanger; A Lemay; J P Raynaud; M Von der Ohe; A T Fazekas
Journal:  J Endocrinol Invest       Date:  1982 Nov-Dec       Impact factor: 4.256

3.  Induction of spermatogenesis in isolated hypogonadotropic hypogonadism with exogenous human chorionic gonadotropin.

Authors:  R Luboshitzky; G Dickstein; D Barzilai
Journal:  J Endocrinol Invest       Date:  1981 Apr-Jun       Impact factor: 4.256

4.  Effects of the duration of therapy with the LHRH agonist D-ser (BUT)6 Azgly10-LHRH (ICI 118-630) on the steroid hormone content and the morphology of human testicular tissue in the treatment of patients with advanced prostate cancer.

Authors:  W Kuber; G Viehberger; R Zeillinger; J Spona
Journal:  Urol Res       Date:  1991
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.